StocksFundsScreenerSectorsWatchlists
IDXX

IDXX - IDEXX Laboratories Inc Stock Price, Fair Value and News

489.70USD-1.59 (-0.32%)Market Closed

Market Summary

IDXX
USD489.70-1.59
Market Closed
-0.32%

IDXX Stock Price

View Fullscreen

IDXX RSI Chart

IDXX Valuation

Market Cap

40.7B

Price/Earnings (Trailing)

48.15

Price/Sales (Trailing)

11.11

EV/EBITDA

33.55

Price/Free Cashflow

52.65

IDXX Price/Sales (Trailing)

IDXX Profitability

Operating Margin

59.82%

EBT Margin

28.99%

Return on Equity

56.92%

Return on Assets

25.92%

Free Cashflow Yield

1.9%

IDXX Fundamentals

IDXX Revenue

Revenue (TTM)

3.7B

Rev. Growth (Yr)

8.81%

Rev. Growth (Qtr)

-1.52%

IDXX Earnings

Earnings (TTM)

845.0M

Earnings Growth (Yr)

12.96%

Earnings Growth (Qtr)

-8.34%

Breaking Down IDXX Revenue

Last 7 days

-4.5%

Last 30 days

-7.2%

Last 90 days

-5.5%

Trailing 12 Months

1.9%

How does IDXX drawdown profile look like?

IDXX Financial Health

Current Ratio

1.57

Debt/Equity

0.42

Debt/Cashflow

1.46

IDXX Investor Care

Shares Dilution (1Y)

0.22%

Diluted EPS (TTM)

10.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20233.4B3.5B3.6B3.7B
20223.3B3.3B3.3B3.4B
20212.9B3.0B3.1B3.2B
20202.5B2.5B2.6B2.7B
20192.3B2.3B2.4B2.4B
20182.0B2.1B2.2B2.2B
20171.8B1.9B1.9B2.0B
20161.6B1.7B1.7B1.8B
20151.5B1.5B1.6B1.6B
20141.4B1.4B1.5B1.5B
20131.3B1.3B1.3B1.4B
20121.2B1.3B1.3B1.3B
20111.1B1.2B1.2B1.2B
20101.1B1.1B1.1B1.1B
200901.0B1.0B1.0B
20080001.0B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of IDEXX Laboratories Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 06, 2024
polewaczyk james f
acquired
3,423,550
422
8,104
executive vice president
Mar 06, 2024
polewaczyk james f
sold
-4,525,600
558
-8,104
executive vice president
Mar 05, 2024
vandebroek sophie v.
sold
-790,427
562
-1,404
-
Mar 05, 2024
vandebroek sophie v.
acquired
345,089
245
1,404
-
Feb 29, 2024
mazelsky jonathan jay
gifted
-
-
-550
president and ceo
Feb 21, 2024
mazelsky jonathan jay
acquired
99,952
206
483
president and ceo
Feb 16, 2024
underberg sharon e.
acquired
99,952
206
483
evp, gc & corporate secretary
Feb 15, 2024
mckeon brian p
acquired
99,952
206
483
evp, cfo and treasurer
Feb 14, 2024
underberg sharon e.
acquired
-
-
1,186
evp, gc & corporate secretary
Feb 14, 2024
schreck michael
sold (taxes)
-65,585
560
-117
executive vice president

1–10 of 50

Which funds bought or sold IDXX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 15, 2024
G&S Capital LLC
reduced
-1.38
-13,089
308,840
0.14%
Apr 15, 2024
MCDONALD PARTNERS LLC
reduced
-20.00
-76,941
269,965
0.07%
Apr 15, 2024
First Bancorp, Inc /ME/
added
0.83
-14,170
724,047
0.55%
Apr 15, 2024
Sovereign Financial Group, Inc.
added
1.84
-2,243
238,649
0.06%
Apr 15, 2024
Manning & Napier Group, LLC
reduced
-79.1
-89,761,700
22,904,000
0.26%
Apr 15, 2024
OLD NATIONAL BANCORP /IN/
reduced
-6.06
-65,514
694,349
0.02%
Apr 15, 2024
Chicago Capital, LLC
reduced
-0.15
-1,497,930
50,656,200
1.54%
Apr 15, 2024
EXCHANGE TRADED CONCEPTS, LLC
added
91.59
621,301
1,340,650
0.04%
Apr 15, 2024
WEST PACES ADVISORS INC.
sold off
-100
-555
-
-%
Apr 15, 2024
JANICZEK WEALTH MANAGEMENT, LLC
added
250
10,678
15,119
-%

1–10 of 50

Are Funds Buying or Selling IDXX?

Are funds buying IDXX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IDXX
No. of Funds

Unveiling IDEXX Laboratories Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
10.09%
8,377,667
SC 13G/A
Jan 24, 2024
blackrock inc.
10.9%
9,054,229
SC 13G/A
Dec 08, 2023
vanguard group inc
10.03%
8,331,697
SC 13G/A
Feb 14, 2023
fundsmith llp
5.37%
4,447,828
SC 13G
Feb 14, 2023
fundsmith llp
5.37%
4,447,828
SC 13G
Feb 09, 2023
vanguard group inc
9.82%
8,132,479
SC 13G/A
Jan 26, 2023
blackrock inc.
10.3%
8,502,881
SC 13G/A
Jan 20, 2023
blackrock inc.
10.3%
8,502,881
SC 13G/A
Feb 10, 2022
vanguard group inc
9.34%
7,923,466
SC 13G/A
Jan 27, 2022
blackrock inc.
10.6%
8,990,586
SC 13G/A

Recent SEC filings of IDEXX Laboratories Inc

View All Filings
Date Filed Form Type Document
Mar 27, 2024
ARS
ARS
Mar 27, 2024
DEF 14A
DEF 14A
Mar 27, 2024
DEFA14A
DEFA14A
Mar 07, 2024
4
Insider Trading
Mar 07, 2024
4
Insider Trading
Mar 06, 2024
144
Notice of Insider Sale Intent
Mar 05, 2024
144
Notice of Insider Sale Intent
Mar 04, 2024
4
Insider Trading
Feb 22, 2024
10-K
Annual Report
Feb 22, 2024
4
Insider Trading

Peers (Alternatives to IDEXX Laboratories Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
177.8B
23.9B
-3.91% -4.78%
37.49
7.44
-10.33% -33.23%
40.7B
3.7B
-7.22% 1.87%
48.15
11.11
8.72% 24.44%
40.1B
6.7B
-4.92% 0.73%
32.43
5.95
-2.81% -6.58%
14.1B
9.3B
0.30% -9.60%
16.52
1.52
-6.38% -9.73%
11.9B
4.1B
-8.95% 15.76%
25.15
2.89
3.86% -2.39%
11.8B
1.9B
-2.43% 101.48%
41.84
6.27
29.17% 15.26%
11.6B
2.5B
13.24% -2.16%
-56.78
4.64
19.93% 67.26%
10.9B
1.1B
0.99% 75.89%
-25.08
10.07
31.99% 20.63%
MID-CAP
2.6B
929.2M
-20.88% -25.40%
1.7K
2.84
28.93% 111.61%
2.0B
563.9M
-3.78% -30.33%
-4.1
3.48
25.45% 26.76%
SMALL-CAP
406.5M
280.3M
-19.03% -7.55%
-2.14
1.45
-12.89% -148.37%
86.5M
31.2M
4.27% -86.20%
-0.98
2.77
5.03% -1.81%
41.5M
9.2M
-6.67% -36.96%
-2.48
4.53
11.85% 44.12%
6.1M
9.0M
-2.70% -65.71%
-0.85
0.68
-53.31% 2.21%
183.8K
25.9M
-50.00% -94.83%
-0.01
0.01
-57.78% -93.11%

IDEXX Laboratories Inc News

Latest updates
Defense World38 hours ago
Yahoo Movies Canada14 Apr 202403:56 pm

IDEXX Laboratories Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-1.5%902916944900829842861837801810826778721722638626605605620576549
Cost Of Revenue2.1%375368371357344335347338345338337307--------249
Gross Profit-4.0%526548573543485507514499456473489471410423379360331345358332300
  S&GA Expenses4.7%14213614114813213013013212812411911511610894.0011610610510110796.00
  R&D Expenses8.0%52.0048.0047.0045.0043.0048.0012340.0045.0040.0038.0038.0039.0038.0032.0033.0035.0034.0032.0032.0030.00
EBITDA Margin-0.1%0.33*0.33*0.33*0.30*0.30*0.29*0.29*0.32*0.32*0.33*0.32*0.31*---------
Interest Expenses7.1%9.009.0011.0013.0014.0011.008.007.007.007.008.008.008.008.009.008.007.007.008.008.009.00
Income Taxes-18.9%45.0056.0062.0054.0041.0053.0039.0048.0029.0044.0049.0036.002.0018.0035.0025.0018.0024.0030.0022.0021.00
Earnings Before Taxes-10.5%240268286268213234171241192219252240177164184137109133156125107
EBT Margin0.5%0.29*0.29*0.28*0.26*0.26*0.25*0.25*0.28*0.28*0.28*0.27*0.27*---------
Net Income-8.3%19521222421417218113219416317520320417514614911290.0010912610386.00
Net Income Margin0.7%0.23*0.23*0.23*0.20*0.20*0.20*0.20*0.22*0.23*0.24*0.24*0.24*---------
Free Cashflow-8.8%21723817314412415136.0083.00178142211104---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets5.6%3,2603,0862,8712,8082,7472,6402,6072,5932,4372,3862,4122,3272,2952,0471,9611,8861,8321,7511,7241,6811,537
  Current Assets8.0%1,4951,3841,1791,1491,1011,0591,0431,0909569381,0011,0981,063869780721680703712698654
    Cash Equivalents36.9%45433213311111399.0011420514414523235138417610581.0090.00104111117124
  Inventory-3.5%380394395391368355333302269258241226210218229212195205197189173
  Net PPE2.2%702687683665649612594593588573550544555548551546534497470449437
  Goodwill1.2%3663623643633623553563613594.0010924324323823523.0024025.00215215214
Liabilities-0.8%1,7751,7891,7771,9672,1382,1642,1501,9531,7471,6301,6641,6241,6621,6061,6871,7781,6551,5491,5531,6291,547
  Current Liabilities-1.9%9529708841,0661,2361,1901,167971764634652621583527541846725627619690770
  Long Term Debt0.7%623619697696694761768773775778780779858853--699----
    LT Debt, Current-50.0%75.0015075.0075.0075.00---75.0075.0012512550.0050.00-------
    LT Debt, Non Current0.7%623619697696694761768773775778780779858853--699----
Shareholder's Equity14.4%1,4851,2971,09484160947645764069075574870363344127310817820317252.00-
  Retained Earnings4.6%4,4454,2504,0383,8143,6003,4273,2463,1142,9202,7582,5822,3802,1762,0011,8551,7061,5961,5051,3961,2711,168
  Additional Paid-In Capital1.7%1,5701,5431,5151,4901,4631,4381,4201,4001,3771,3591,3391,3211,2951,2741,2471,2301,2141,1901,1711,1561,138
Shares Outstanding0.0%83.0083.0083.0083.0083.0084.0084.0084.0085.0085.0085.0086.00---------
Minority Interest----------1.001.001.001.001.000.000.000.000.000.000.000.00
Float---41,325---28,964---53,418---27,736---23,369--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-8.3%249,851272,433200,314183,912173,428189,00065,850114,706209,964187,205233,955124,422218,934193,116208,14227,871155,413132,265137,10234,378135,648
  Share Based Compensation0.0%15,22315,22415,36213,93013,27912,94812,37011,1739,7139,5309,6378,8757,9437,9277,7977,28416,6559,3916,8986,3346,209
Cashflow From Investing-9.3%-30,435-27,838-27,470-39,511-49,229-49,197-55,086-41,838-44,040-49,677-174,663-24,587-15,690-19,460-24,556-49,670-95,911-37,326-34,085-38,206-39,844
Cashflow From Financing-136.6%-101,844-43,038-151,033-146,081-116,720-148,829-91,907-13,480-165,820-221,726-180,217-129,651398-104,184-161,53116,901-74,389-99,751-109,488-2,781-117,806
  Buy Backs5.1%36,85035,070--74,020172,631306,765266,295244,756181,234188,525132,262---182,815140,68985,97520,69254,302105,607

IDXX Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:   
Total revenue$ 3,660,953$ 3,367,324$ 3,215,360
Cost of Revenue:   
Total cost of revenue1,470,9831,362,9861,325,928
Gross profit2,189,9702,004,3381,889,432
Expenses:   
Sales and marketing566,066524,505486,735
General and administrative335,825326,248309,660
Research and development190,951254,820161,009
Income from operations1,097,128898,765932,028
Interest expense(41,581)(39,858)(29,808)
Interest income5,6291,065434
Income before provision for income taxes1,061,176859,972902,654
Provision for income taxes216,134180,883157,810
Net income845,042679,089744,844
Less: Net (loss) attributable to noncontrolling interest00(1)
Net income attributable to IDEXX Laboratories, Inc. stockholders$ 845,042$ 679,089$ 744,845
Earnings per Share:   
Basic (in USD per share)$ 10.17$ 8.12$ 8.74
Diluted (in USD per share)$ 10.06$ 8.03$ 8.60
Weighted Average Shares Outstanding:   
Basic (in shares)83,06683,62385,200
Diluted (in shares)83,97884,60086,572
Product revenue   
Revenue:   
Total revenue$ 2,089,936$ 1,928,773$ 1,875,308
Cost of Revenue:   
Total cost of revenue717,951656,511656,823
Service revenue   
Revenue:   
Total revenue1,571,0171,438,5511,340,052
Cost of Revenue:   
Total cost of revenue$ 753,032$ 706,475$ 669,105

IDXX Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current Assets:  
Cash and cash equivalents$ 453,932$ 112,546
Accounts receivable, net of allowance of $9,501 in 2023 and $8,265 in 2022457,445400,619
Inventories380,282367,823
Other current assets203,595220,489
Total current assets1,495,2541,101,477
Long-Term Assets:  
Property and equipment, net702,177649,474
Operating lease right-of-use assets115,499118,618
Goodwill365,961361,795
Intangible assets, net84,50097,672
Other long-term assets496,534417,729
Total long-term assets1,764,6711,645,288
TOTAL ASSETS3,259,9252,746,765
Current Liabilities:  
Accounts payable110,643110,221
Accrued liabilities478,712433,662
Credit facility250,000579,000
Current portion of long-term debt74,99774,982
Current portion of deferred revenue37,19537,938
Total current liabilities951,5471,235,803
Long-Term Liabilities:  
Deferred income tax liabilities7,2358,150
Long-term debt, net of current portion622,883694,387
Long-term deferred revenue, net of current portion28,53330,862
Long-term operating lease liabilities99,671101,239
Other long-term liabilities65,52667,587
Total long-term liabilities823,848902,225
Total liabilities1,775,3952,138,028
Commitments and Contingencies (Note 16)
Stockholders’ Equity:  
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 107,506 shares in 2023 and 107,193 shares in 2022; Outstanding: 83,032 shares in 2023 and 82,894 shares in 202210,75110,719
Additional paid-in capital1,569,5651,463,215
Deferred stock units: Outstanding: 59 units in 2023 and 58 units in 20225,5305,182
Retained earnings4,444,5713,599,529
Accumulated other comprehensive loss(71,206)(77,796)
Treasury stock, at cost: 24,474 shares in 2023 and 24,299 shares in 2022(4,474,681)(4,392,112)
Total IDEXX Laboratories, Inc. stockholders’ equity1,484,530608,737
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 3,259,925$ 2,746,765
IDXX
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; OPTI SARS-CoV-2 RT-PCR test kit for human COVID-19 testing; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
 CEO
 WEBSITEidexx.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES11000

IDEXX Laboratories Inc Frequently Asked Questions


What is the ticker symbol for IDEXX Laboratories Inc? What does IDXX stand for in stocks?

IDXX is the stock ticker symbol of IDEXX Laboratories Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of IDEXX Laboratories Inc (IDXX)?

As of Mon Apr 15 2024, market cap of IDEXX Laboratories Inc is 40.84 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IDXX stock?

You can check IDXX's fair value in chart for subscribers.

What is the fair value of IDXX stock?

You can check IDXX's fair value in chart for subscribers. The fair value of IDEXX Laboratories Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of IDEXX Laboratories Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IDXX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is IDEXX Laboratories Inc a good stock to buy?

The fair value guage provides a quick view whether IDXX is over valued or under valued. Whether IDEXX Laboratories Inc is cheap or expensive depends on the assumptions which impact IDEXX Laboratories Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IDXX.

What is IDEXX Laboratories Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, IDXX's PE ratio (Price to Earnings) is 48.33 and Price to Sales (PS) ratio is 11.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IDXX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on IDEXX Laboratories Inc's stock?

In the past 10 years, IDEXX Laboratories Inc has provided 0.236 (multiply by 100 for percentage) rate of return.